HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology

Angela N. Bartley, Mary Kay Washington, Christina B. Ventura, Nofisat Ismaila, Carol Colasacco, Al B. Benson, Alfredo Carrato, Margaret L. Gulley, Dhanpat Jain, Sanjay Kakar, Helen J. Mackay, Catherine Streutker, Laura Tang, Megan Troxell, Jaffer A. Ajani

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

CONTEXT: ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the assessment of HER2 in patients with GEA.

OBJECTIVES: To establish an evidence-based guideline for HER2 testing in patients with GEA, to formalize the algorithms for methods to improve the accuracy of HER2 testing while addressing which patients and tumor specimens are appropriate, and to provide guidance on clinical decision making.

DESIGN: The College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology convened an expert panel to conduct a systematic review of the literature to develop an evidence-based guideline with recommendations for optimal HER2 testing in patients with GEA.

RESULTS: The panel is proposing 11 recommendations with strong agreement from the open-comment participants.

RECOMMENDATIONS: The panel recommends that tumor specimen(s) from all patients with advanced GEA, who are candidates for HER2-targeted therapy, should be assessed for HER2 status before the initiation of HER2-targeted therapy. Clinicians should offer combination chemotherapy and a HER2-targeted agent as initial therapy for all patients with HER2-positive advanced GEA. For pathologists, guidance is provided for morphologic selection of neoplastic tissue, testing algorithms, scoring methods, interpretation and reporting of results, and laboratory quality assurance.

CONCLUSIONS: This guideline provides specific recommendations for assessment of HER2 in patients with advanced GEA while addressing pertinent technical issues and clinical implications of the results.

Original languageEnglish (US)
Pages (from-to)647-669
Number of pages23
JournalAmerican Journal of Clinical Pathology
Volume146
Issue number6
DOIs
StatePublished - Dec 1 2016
Externally publishedYes

Fingerprint

Adenocarcinoma
Guidelines
TYK2 Kinase
Pathologists
Clinical Decision-Making
Therapeutics
Combination Drug Therapy
Neoplasms
Research Design
Biomarkers

Keywords

  • Gastroesophageal adenocarcinoma
  • Guidelines
  • HER2 testing

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma : Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. / Bartley, Angela N.; Washington, Mary Kay; Ventura, Christina B.; Ismaila, Nofisat; Colasacco, Carol; Benson, Al B.; Carrato, Alfredo; Gulley, Margaret L.; Jain, Dhanpat; Kakar, Sanjay; Mackay, Helen J.; Streutker, Catherine; Tang, Laura; Troxell, Megan; Ajani, Jaffer A.

In: American Journal of Clinical Pathology, Vol. 146, No. 6, 01.12.2016, p. 647-669.

Research output: Contribution to journalArticle

Bartley, AN, Washington, MK, Ventura, CB, Ismaila, N, Colasacco, C, Benson, AB, Carrato, A, Gulley, ML, Jain, D, Kakar, S, Mackay, HJ, Streutker, C, Tang, L, Troxell, M & Ajani, JA 2016, 'HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology', American Journal of Clinical Pathology, vol. 146, no. 6, pp. 647-669. https://doi.org/10.1093/ajcp/aqw206
Bartley, Angela N. ; Washington, Mary Kay ; Ventura, Christina B. ; Ismaila, Nofisat ; Colasacco, Carol ; Benson, Al B. ; Carrato, Alfredo ; Gulley, Margaret L. ; Jain, Dhanpat ; Kakar, Sanjay ; Mackay, Helen J. ; Streutker, Catherine ; Tang, Laura ; Troxell, Megan ; Ajani, Jaffer A. / HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma : Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. In: American Journal of Clinical Pathology. 2016 ; Vol. 146, No. 6. pp. 647-669.
@article{b30418794b1c4dfb92602df4430d8364,
title = "HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology",
abstract = "CONTEXT: ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the assessment of HER2 in patients with GEA.OBJECTIVES: To establish an evidence-based guideline for HER2 testing in patients with GEA, to formalize the algorithms for methods to improve the accuracy of HER2 testing while addressing which patients and tumor specimens are appropriate, and to provide guidance on clinical decision making.DESIGN: The College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology convened an expert panel to conduct a systematic review of the literature to develop an evidence-based guideline with recommendations for optimal HER2 testing in patients with GEA.RESULTS: The panel is proposing 11 recommendations with strong agreement from the open-comment participants.RECOMMENDATIONS: The panel recommends that tumor specimen(s) from all patients with advanced GEA, who are candidates for HER2-targeted therapy, should be assessed for HER2 status before the initiation of HER2-targeted therapy. Clinicians should offer combination chemotherapy and a HER2-targeted agent as initial therapy for all patients with HER2-positive advanced GEA. For pathologists, guidance is provided for morphologic selection of neoplastic tissue, testing algorithms, scoring methods, interpretation and reporting of results, and laboratory quality assurance.CONCLUSIONS: This guideline provides specific recommendations for assessment of HER2 in patients with advanced GEA while addressing pertinent technical issues and clinical implications of the results.",
keywords = "Gastroesophageal adenocarcinoma, Guidelines, HER2 testing",
author = "Bartley, {Angela N.} and Washington, {Mary Kay} and Ventura, {Christina B.} and Nofisat Ismaila and Carol Colasacco and Benson, {Al B.} and Alfredo Carrato and Gulley, {Margaret L.} and Dhanpat Jain and Sanjay Kakar and Mackay, {Helen J.} and Catherine Streutker and Laura Tang and Megan Troxell and Ajani, {Jaffer A.}",
year = "2016",
month = "12",
day = "1",
doi = "10.1093/ajcp/aqw206",
language = "English (US)",
volume = "146",
pages = "647--669",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "6",

}

TY - JOUR

T1 - HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma

T2 - Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology

AU - Bartley, Angela N.

AU - Washington, Mary Kay

AU - Ventura, Christina B.

AU - Ismaila, Nofisat

AU - Colasacco, Carol

AU - Benson, Al B.

AU - Carrato, Alfredo

AU - Gulley, Margaret L.

AU - Jain, Dhanpat

AU - Kakar, Sanjay

AU - Mackay, Helen J.

AU - Streutker, Catherine

AU - Tang, Laura

AU - Troxell, Megan

AU - Ajani, Jaffer A.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - CONTEXT: ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the assessment of HER2 in patients with GEA.OBJECTIVES: To establish an evidence-based guideline for HER2 testing in patients with GEA, to formalize the algorithms for methods to improve the accuracy of HER2 testing while addressing which patients and tumor specimens are appropriate, and to provide guidance on clinical decision making.DESIGN: The College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology convened an expert panel to conduct a systematic review of the literature to develop an evidence-based guideline with recommendations for optimal HER2 testing in patients with GEA.RESULTS: The panel is proposing 11 recommendations with strong agreement from the open-comment participants.RECOMMENDATIONS: The panel recommends that tumor specimen(s) from all patients with advanced GEA, who are candidates for HER2-targeted therapy, should be assessed for HER2 status before the initiation of HER2-targeted therapy. Clinicians should offer combination chemotherapy and a HER2-targeted agent as initial therapy for all patients with HER2-positive advanced GEA. For pathologists, guidance is provided for morphologic selection of neoplastic tissue, testing algorithms, scoring methods, interpretation and reporting of results, and laboratory quality assurance.CONCLUSIONS: This guideline provides specific recommendations for assessment of HER2 in patients with advanced GEA while addressing pertinent technical issues and clinical implications of the results.

AB - CONTEXT: ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the assessment of HER2 in patients with GEA.OBJECTIVES: To establish an evidence-based guideline for HER2 testing in patients with GEA, to formalize the algorithms for methods to improve the accuracy of HER2 testing while addressing which patients and tumor specimens are appropriate, and to provide guidance on clinical decision making.DESIGN: The College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology convened an expert panel to conduct a systematic review of the literature to develop an evidence-based guideline with recommendations for optimal HER2 testing in patients with GEA.RESULTS: The panel is proposing 11 recommendations with strong agreement from the open-comment participants.RECOMMENDATIONS: The panel recommends that tumor specimen(s) from all patients with advanced GEA, who are candidates for HER2-targeted therapy, should be assessed for HER2 status before the initiation of HER2-targeted therapy. Clinicians should offer combination chemotherapy and a HER2-targeted agent as initial therapy for all patients with HER2-positive advanced GEA. For pathologists, guidance is provided for morphologic selection of neoplastic tissue, testing algorithms, scoring methods, interpretation and reporting of results, and laboratory quality assurance.CONCLUSIONS: This guideline provides specific recommendations for assessment of HER2 in patients with advanced GEA while addressing pertinent technical issues and clinical implications of the results.

KW - Gastroesophageal adenocarcinoma

KW - Guidelines

KW - HER2 testing

UR - http://www.scopus.com/inward/record.url?scp=85014096639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014096639&partnerID=8YFLogxK

U2 - 10.1093/ajcp/aqw206

DO - 10.1093/ajcp/aqw206

M3 - Article

C2 - 28077399

AN - SCOPUS:85014096639

VL - 146

SP - 647

EP - 669

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 6

ER -